The O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham is partnering with the GO2 Foundation for Lung Cancer in a study—together with Vanderbilt University Medical Center and Augusta University—to determine how to improve participation from Black communities in lung cancer clinical trials.
In its first clinical trial in patients with a hard-to-treat form of uterine cancer, a targeted drug that subjects tumor cells to staggering levels of DNA damage caused tumors to shrink in nearly one-third of patients, investigators at Dana-Farber Cancer Institute found.
CYNK-001, a natural killer cell therapy, has received Fast Track designation from FDA for the treatment of adults with recurrent glioblastoma multiforme.
Geneseeq Technology Inc. and Illumina Inc. are working together to develop comprehensive in-vitro diagnostic NGS testing kits (IVD kits) for cancer, using Illumina’s NextSeq 550 Dx sequencing platform.
M2Gen and Merck have entered a new five-year agreement to advance cancer research.
Clayton, Dubilier & Rice funds, the Merck Global Health Innovation Fund (Merck GHI), and McKesson Ventures are investing in M2Gen, an oncology data and informatics platform focused on transforming cancer care, in partnership with its existing shareholders.
FDA will hold a three-day meeting of the Oncologic Drugs Advisory Committee April 27-29 to consider five indications that received accelerated approvals, but that have not been shown to produce a clinical benefit in confirmatory trials.
NCI recently announced a master plan for its $500 million Childhood Cancer Data Initiative, a pilot project designed to set the stage for building a publicly accessible, comprehensive data federation for all cancers (The Cancer Letter, Dec. 4, 2020).
Xiongbin Lu was named co-leader of the Experimental and Developmental Therapeutics Research Program at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.
Regina Bou Puerto, Mijin Kim named 2021 Kravis Women in Science Endeavor fellowship grant recipients
Regina Bou Puerto and Mijin Kim, Sloan Kettering Institute researchers, were named 2021 Marie-Josée Kravis Women in Science Endeavor (Kravis WiSE) fellowship grant recipients.
